You are here

Daiichi Sankyo

Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer

Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer

Pharmaceutical Business Review

antibody-drug conjugate

triple negative breast cancer

clinical trials

Flag link:

AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful

AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful

Fierce Pharma

University of Oxford

Flag link:

Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC

Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC

BioSpace

companion diagnostics

non-small cell lung cancer

Flag link:

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

Pharmaforum

colorectal cancer

Flag link:

AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a week

AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a week

Pharmaforum

metastatic non-small-cell lung cancer

Flag link:

AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug

AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug

Pharmaceutical Business Review

breakthrough therapy

Flag link:

Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan

Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan

Pharmaceutical Business Review

axicabtagene ciloleucel

relapsed or refractory diffuse large B-cell lymphoma

Flag link:

Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer

Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer

Fierce Biotech

clinical trials

HER2-positive non-small cell lung cancer

Flag link:

AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch

AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch

Fierce Pharma

clinical trials

Flag link:

Antibody-drug conjugates on the march

Antibody-drug conjugates on the march

Pharmaforum

antibody-drug conjugate

Flag link:

Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study

Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study

Endpoints

trastuzumab deruxtecan

Flag link:

FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filing

FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filing

Pharmaforum

advanced breast cancer

Flag link:

Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals

Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals

BioPharma Dive

trastuzumab deruxtecan

Flag link:

SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance

SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance

EP Vantage

trastuzumab deruxtecan

Flag link:

Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute

Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute

BioSpace

Seattle Genetics

antibody-drug conjugate

Flag link:

Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug

Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug

Endpoints

clinical trials

diabetic nephropathy

Flag link:

Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates

Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates

Pharmaforum

Seattle Genetics

trastuzumab deruxtecan

Flag link:

Daiichi sues Seattle Genetics over tech used in high-profile ADC

Daiichi sues Seattle Genetics over tech used in high-profile ADC

Fierce Biotech

Seattle Genetics

antibody-drug conjugate

Flag link:

Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny

Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny

Fierce Pharma

Flag link:

Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute

Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute

Pharmaceutical Business Review

Sarah Cannon Research Institute

antibody-drug conjugate

clinical trials

Flag link:

Pages